The introduction of HB 1171 is expected to have a significant impact on the healthcare landscape in Illinois. By ensuring that rebate amounts are incorporated into the cost-sharing calculation, the legislation aims to reduce premiums for health plans through appropriate application of excess rebates. This could lead to lower healthcare costs for consumers while prompting insurers to adapt their pricing and coverage strategies in response to these requirements. The bill's framework may also promote transparency in how rebates are utilized by insurance companies, fostering consumer trust and understanding.
Summary
House Bill 1171 amends the Illinois Insurance Code to address cost sharing for prescription drugs. Specifically, it mandates that from January 1, 2026, all group or individual accident and health insurance policies must calculate a covered individual's cost sharing at the point of sale based on a price that reflects a reduction equivalent to 100% of any rebates received related to the prescription drug. This provision aims to alleviate out-of-pocket expenses for insured individuals when purchasing medication, potentially increasing accessibility to necessary treatments.
Contention
While supporters of the bill laud its intention to lower healthcare costs and increase drug affordability for patients, opponents may raise concerns regarding its feasibility and the potential implications for insurance companies. There may be questions about whether insurers can retain adequate financial stability while absorbing the costs related to expanded coverage dictated by this bill. Moreover, some stakeholders could argue that the true effectiveness of the bill hinges on how consistently it is implemented and monitored by the Department of Insurance, as well as the broader market response to such regulatory changes.
Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.
Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.